Big pharma, Partnering, Pharma

Xention and Servier pharma partners for XEN-D0103

Posted on 03 October 2013

Tags: , , , ,

XENTION and SERVIER pharma partners by entering into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation .

Under the terms of the agreement, Servier has received an option to acquire certain intellectual property rights and to further develop and commercialise XEN-D0103 in all territories except the USA and Japan.

All rights in the USA and Japan will be retained by Xention.

During the option period, the pharma partnerswill undertake a joint programme of clinical development of XEN-D0103 undertaking two phase 2 clinical studies aimed at demonstrating the efficacy of XEN-D0103 in reducing AF burden in paroxysmal AF.

In addition to an upfront fee, Servier will pay an option fee as well as a series of milestones totalling €120 million.

When Servier exercises its option, it will be responsible for the further clinical development and commercialisation of XEN-D0103 within its territories.

XEN-D0103 is a potent and selective blocker of Kv1.5, a potassium channel expressed in the atria, which represents an exciting new target for atrial fibrillation.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on Servier company profile, recent partnering, M&A and financing news and articles

Report: Partnering Deals and Alliances with Servier

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply